You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 10,071,962


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,071,962
Title:Androgen receptor modulators and methods for their use
Abstract: Compounds having a structure of Structure I: ##STR00001## or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.6, Y.sup.1 and Y.sup.2 are as defined herein, and wherein at least one of R.sup.3 or R.sup.4 is a straight-chain C.sub.1-C.sub.6 haloalkyl, are provided. Uses of such compounds for treatment of various indications, including prostate cancer, as well as methods of treatment involving such compounds are also provided.
Inventor(s): Yan; Luping (Vancouver, CA), Andersen; Raymond J. (Vancouver, CA), Sadar; Marianne Dorothy (West Vancouver, CA), Mawji; Nasrin R. (Burnaby, CA), Banuelos; Carmen Adriana (Richmond, CA)
Assignee: British Columbia Cancer Agency Branch (Vancouver, CA) The University of British Columbia (Vancouver, CA)
Application Number:15/626,526
Patent Claims:1. A pharmaceutical composition comprising a compound of structure (I), an additional therapeutic agent and a pharmaceutically acceptable carrier; wherein the compound of structure (I) has the following formula: ##STR00099## or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein: Y.sup.1 and Y.sup.2 are each independently O or S; R.sup.1 is H, C.sub.1-C.sub.6 alkyl or C.sub.1-C.sub.6 haloalkyl; R.sup.2 is H, --C(.dbd.O)R.sup.7 or --S(O).sub.nR.sup.8; R.sup.3 and R.sup.4 are straight-chain C.sub.1-C.sub.6 haloalkyl; R.sup.5 and R.sup.6 are each independently H, OH, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 haloalkyl or C.sub.1-C.sub.6 haloalkoxy; R.sup.7 is C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 haloalkyl or C.sub.1-C.sub.6 haloalkoxy; R.sup.8 is C.sub.1-C.sub.6 alkyl C.sub.1-C.sub.6 haloalkyl; is a carbon-carbon double bond or a carbon-carbon single bond, such that all valences are satisfied; and n is 0, 1 or 2; and wherein the additional therapeutic agent is for treating prostate cancer, breast cancer, ovarian cancer, endometrial cancer, bladder cancer, pancreatic cancer, hepatocellular cancer, kidney cancer, liver cancer, salivary gland carcinoma, hair loss, acne, hirsutism, ovarian cysts, polycystic ovary disease, precocious puberty, spinal and bulbar muscular atrophy or age-related macular degeneration.

2. The pharmaceutical composition of claim 1, wherein the additional therapeutic agent is enzalutamide, Galeterone, ARN-509, ODM-201, abiraterone, bicalutamide, nilutamide, flutamide, cyproterone acetate, docetaxel, Bevacizumab (Avastin), OSU-HDAC42, VITAXIN (humanized form of LM609), sunitinib (N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl- ]-2,4-dimethyl-1H-pyrrole-3-carboxamide), ZD-4054, Cabazitaxel (XRP-6 258), MDX-010 (Ipilimumab), OGX 427, OGX 011, finasteride, dutasteride, turosteride, bexlosteride, izonsteride, FCE 28260, SKF105,111, Radium 233 or prednisone.

3. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is formulated for topical administrations.

4. A method for modulating androgen receptor (AR) activity, the method comprising administering the pharmaceutical composition of 1 to a subject in need thereof, wherein modulating androgen receptor (AR) activity is for the treatment of one or more of the following: prostate cancer, breast cancer, ovarian cancer, endometrial cancer, bladder cancer, pancreatic cancer, hepatocellular cancer, kidney cancer, liver cancer, salivary gland carcinoma, hair loss, acne, hirsutism, ovarian cysts, ovary disease, precocious puberty, spinal and bulbar muscular atrophy, polycystic or age-related macular degeneration.

5. The method of claim 4, wherein the method is for treatment of prostate cancer.

6. The method of claim 5, wherein the prostate cancer is castration resistant prostate cancer.

7. The method of claim 5, wherein the prostate cancer is androgen-dependent prostate cancer.

8. The method of claim 4, wherein the administration is topical.

9. The method of claim 4, wherein the administration is intravenous.

10. The pharmaceutical composition of claim 1, wherein the compound has the following structure (Ia): ##STR00100##

11. The pharmaceutical composition of claim 10, wherein at least one of Y.sup.1 and Y.sup.2 is 0.

12. The pharmaceutical composition of claim 10, wherein at least one of R.sup.1 and R.sup.2 is H.

13. The pharmaceutical composition of claim 10, wherein R.sup.2 is --C(.dbd.O)R.sup.7 or --S(O).sub.nR.sup.8.

14. The method pharmaceutical composition of claim 13, wherein R.sup.7 is ethyl, t-butyl ##STR00101## or t-butoxy; or R.sup.8 is ethyl.

15. The pharmaceutical composition of claim 13, wherein n is 2.

16. The pharmaceutical composition of claim 10, wherein R.sup.5 is C.sub.1-C.sub.6 alkoxy or R.sup.6 is H.

17. The pharmaceutical composition of claim 16, wherein C.sub.1-C.sub.6 alkoxy is methoxy.

18. The pharmaceutical composition of claim 10, wherein at least one of R.sup.3 or R.sup.4 is a straight-chain C.sub.1-C.sub.6 chloroalkyl.

19. The pharmaceutical composition of claim 18, wherein C.sub.1-C.sub.6 chloroalkyl comprises a perchloro-substituted carbon.

20. The pharmaceutical composition of claim 10, wherein R.sup.3 or R.sup.4, or both, is 3,3,3-trichloropropyl.

21. The pharmaceutical composition of claim 10, wherein is a carbon-carbon double bond.

22. The pharmaceutical composition of claim 1, wherein the compound has one of the following structures: ##STR00102## ##STR00103## ##STR00104## ##STR00105## ##STR00106## ##STR00107##

23. The pharmaceutical composition of claim 1, wherein the compound has the following structure (Ib), structure (Ic), or structure (Id): ##STR00108##

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.